Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapies-Reference-Cited by-同舟云学术

Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapies

Published:2018-03 Issue:3 Volume:29 Page:573-577
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Korn E.L.,Freidlin B.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/3/573/24530885/mdx788.pdf

Reference31 articles.

1. Food and Drug Administration. Non-inferiority clinical trials to establish effectiveness: guidance for industry 2016; https://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf.

2. Non-inferiority cancer clinical trials: scope and purposes underlying their design;Riechelmann;Ann Oncol,2013

3. Statistical issues and recommendations for noninferiority trials in oncology: a systematic review;Tanaka;Clin Cancer Res,2012

4. Non-inferiority trials: design concepts and issues – the encounters of academic consultants in statistics;D’Agostino;Stat Med,2003

5. Design and analysis of non-inferiority trials in oncology;Rothmann;Stat Med,2003

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bayesian Multi-Arm De-Intensification Designs;Bayesian Analysis;2024-01-01

2. Information fraction estimation: Strategies for a phase 3 non‐inferiority maximum duration design with time to event outcome;Pharmaceutical Statistics;2023-07-26

3. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study;BMC Cancer;2023-05-02

4. Early Termination of Clinical Trials for Futility — Considerations for a Data and Safety Monitoring Board;NEJM Evidence;2022-06-28

5. Futility Analysis;Wiley StatsRef: Statistics Reference Online;2022-02-15